TRIPASS XR تري باس

 

for Parkinson’s disease, 1265

Cogentin (see Benztropine)

Colazal (see Balsalazide)

Colchicine, 128, 913, 915

drug interaction, 914t

Colesevelam, 127, 942t

for type 2 diabetes, 1130–1131

Colestipol, 127

Colfosceril, 2170

Colistimethate, 463

for cystic fibrosis, 461t

Colistin, 461t

Colloids, 358–359

Combination vaccines, 1356t

Combined androgen blockade (CAB), 2090

Compazine (see Prochlorperazine)

Conivaptan, 128, 914t

for hyponatremia, 579

Conjugated equine estrogen (Premarin), 1033t

Conjugated estrogen, 1037

Conjugated pneumococcal vaccine (PCV), 1355

Contrave (see Naltrexone/Bupropion)

ConvaTec (see Silver sulfadiazine cream)

Corlanor (see Ivabradine)

Corlopam (see Fenoldopam)

Corticosteroids, 523, 712t, 713t, 721, 899–900, 928, 942t, 1372, 1627, 1639, 1652, 1995–1996

for acne, 827

for acute asthma, 392–393

for acute gout, 913

for adult meningitis, 1377

for AECOPD, 1408

for anaphylaxis, 687–688, 689t

antibiotics with, 819

for bacterial meningitis, 1372

for brain abscess, 1382

for cataracts, 1166–1167

for chronic asthma, 395–397

for CINV, 471

for COPD, 417–418, 422–423

Crohn’s disease, 529

during delivery, 989, 994

for depressive disorders, 1815t

for diabetes, 1146

for drug-induced lupus, 692

drug interaction with smoking, 1907t

for FSGS patients, 628

for hypercalcemia, 589t, 591

hyperglycemia and, 1146

for hyperthyroidism, 1059t

and hypokalemia, 583t

infection and, 1322

for inflammatory bowel disease, 521t, 523

for inflammatory response in CF, 459

intra-articular, 900, 902–904

for JIA, 902–904

management of acute PJP, 1604

for migraine headache, 1240

for MS, 1222, 1228

ophthalmic, 1165–1167, 1166t

for ophthalmopathy, 1067

for PMR and GCA, 925

for PPROM, 994

for psoriasis, 835t, 836–837

for RA, 881, 883

for rhinitis, 442

for SARS, 1660

for septic shock, 372–373

for skin, 813–820, 814–815t, 817t

adverse drug effects of, 816–818

contraindications to, 813, 815

indications for, 813

for systemic lupus erythematosus, 708

teratogenic effects, 973t

therapy for LN, 626

therapy for Wegener granulomatosis, 628

tuberculous meningitis and, 1444

ulcerative colitis, 525–526

Corticotropin, 913

Cosmegen (see Dactinomycin)

Cotrimoxazole, 1720

for aerobic gram-positive cocci, 1326t

for gram-negative aerobes, 1327t

COX-1 (see Cyclooxygenase-1 (COX-1))

COX-2 (see Cyclooxygenase-2 (COX-2))

Creatine, 1265

Crinone (see Progesterone vaginal gel)

Crizotinib, 128, 470t, 2006

Crofelemer, for infectious diarrhea, 1449

Cromolyn, 459

for allergic rhinitis, 434

for rhinitis, 438–439

Cromolyn sodium (Crolom; Nasalcrom), 439t, 440t

Cromolyn sodium ophthalmic, 1165

Crotamiton, 1705t

CRT (see Cardiac resynchronization therapy (CRT))

Crystalloids

composition and properties of, 353t

for hemorrhagic shock, 355

CSA (see Cyclosporine (CSA))

Cubicin (see Daptomycin)

Cyanocobalamin, 914t (see also Vitamin B12

)

for pernicious anemia, 1935

CYC (see Cyclophosphamide (CYC))

Cyclobenzaprine, 1186t, 1194t

Cyclooxygenase-1 (COX-1), 490

Cyclooxygenase-2 (COX-2), 694, 870, 870t, 887, 888t, 889, 913

for systemic lupus erythematosus, 706–707

Cyclophosphamide (CYC), 469t, 470t, 626, 709, 712t, 713t, 917t, 924, 1971, 1977, 1979t, 1987, 1994t,

2004, 2005, 2018, 2037t, 2040t, 2042

for ALL, 2017t

for breast cancer, 2052, 2053

for CLL, 2033

and gonadal toxicity, 1997–1998

and hemorrhagic cystitis, 2021

neurotoxicity of, 1985t

for ophthalmopathy, 1067

for rhabdomyosarcoma, 2010–2011

for T-cell lymphomas, 2020t

teratogenic effects, 973t

therapy for Wegener granulomatosis, 627–628

Cycloserine, for tuberculosis, 1430t

Cyclosporine (CSA), 120t, 127, 214, 528, 928, 942t

for acute UC, 524

for inflammatory bowel disease, 521t

for kidney transplantation, 730–733, 737

for ophthalmopathy, 1067

p. 2297

p. 2298

in organ transplantation, 721–722, 725, 728

for psoriasis, 836t, 840–841

for RA, 883

therapy for LN, 626

CYP2D6 inhibitor, 1774, 1778

CYP3A4 inhibitor, 1743, 1746

and sleep, 1774

Cyproheptadine, for pruritus, 819

Cyproterone, for acne, 829

Cytarabine, 469t, 1985–1986, 1994t, 1996, 1997, 1998, 2018, 2021, 2026, 2028, 2031

adverse effects of, 2028

for aggressive lymphomas, 2043

for ALL, 2017t

for AML, 2025

gonadal toxicity of, 1998

neurotoxicity of, 1985t

for T-cell lymphomas, 2020t

Cytomegalovirus hyperimmune globulin, 743

Cytovene (see Ganciclovir)

D

D-penicillamine, 881

Dabigatran, 128, 187, 1307t

for DVT, 189

for stroke prevention, 178, 317

for warfarin therapy, 200

Dabrafenib, 470t

Dacarbazine (DTIC), 469t, 1978–1979t, 1991t, 2040t

Daclatasvir, for HAV, 1688

Dacogen (see Decitabine (Dacogen))

Dactinomycin (Cosmegen), 469t, 1978–1979t

hepatotoxicity of, 2007–2008

for rhabdomyosarcoma, 2010, 2011

Dalbavancin (Dalvance), 1393

adverse effects of, 1333t

for aerobic gram-positive cocci, 1326t

Dalfampridine, 1223

Dalfopristin/Quinupristin (Synercid), 1325t

adverse effects of, 1333t

Dalteparin, 177t, 188t, 189

LMWH, 656

Dalvance (see Dalbavancin)

Danaparoid, in patients with HIT, 657

Danazol, 120t

adverse effects, 1022

for endometriosis, 1020

for PMDD, 1027

Dantrolene, 1224

Dapagliflozin, 1129–1130

Dapsone, 1604

Daptacel, 1357

Daptomycin (Cubicin), 1326t, 1393

adverse effects of, 1333t

for aerobic gram-positive cocci, 1326t

for CAPD-associated peritonitis, 1476t

dosing of, 1337t

for endocarditis, 1396

enterococcal endocarditis and, 1399

MRSA, 1550

for skin and soft tissue infections, 1549

Darbepoetin alfa (Aranesp), 615–616

for anemia, 1942

Darifenacin, 2251

Darunavir (DRV), 128, 942t, 1579t

Dasabuvir, for HAV, 1689

Dasatinib (Sprycel), 470t, 914t, 1989, 1990, 2031

Daunorubicin (Cerubidine), 469t, 1977, 1979t, 1981t, 1988, 2028

for AML, 2025

and hepatic dysfunction, 1996t

for T-cell lymphomas, 2020t

dDAVP (see desmopressin)

ddl (see Didanosine (ddI))

Decadron (see Dexamethasone)

Decitabine (Dacogen), 469t

Decongestant

for allergic rhinitis, 434, 434t

for rhinitis, 437–438

DEET (see N,N-diethyl-m-toluamide (DEET))

Deferasirox, for vaso-occlusive complications, 1940, 1941

Deferoxamine (DFO)

in iron toxicity, 73

for vaso-occlusive complications, 1940, 1941

Defibrillator, role of, 300

Dehydroepiandrosterone sulfate (DHEAS), 826

DEKAs Plus chewable tablet, 457t

DEKAs Plus liquid, 457t

DEKAs Plus softgel capsules, 457t

Delavirdine (DLV), for HIV, 1580t

∆-9-tetrahydrocannabinol (THC), 1885

Delzicol (see Mesalamine)

Demeclocycline, 579

Demerol (see Meperidine)

Denavir (see Penciclovir cream)

Denileukin diftitox, 469t

Denosumab, 2038, 2277t, 2284–2285

androgen deprivation therapy, 2097

for prostate cancer, 2096

Deoxycholate, for sepsis, 2186t

Depacon, 1299

Depo-Provera, 947–948

Depot medroxyprogesterone acetate (DMPA), 1021

Desferal, in iron toxicity, 73

Desiccated thyroid, 1048–1049

Desipramine (see also Antidepressants)

for depressive disorders, 1819t, 1821t

Desloratadine (Clarinex), 433t

for rhinitis, 437

Desmopressin (dDAVP), 647

Desogestrel, 936–938t, 945

Desvenlafaxine (Pristiq)

for depressive disorders, 1819t, 1821t

for diabetes, 2226t

for serotonin, 1826

for vasomotor symptoms, 1036t

Dexamethasone (Decadron), 472t, 475–476, 994, 1639, 2036, 2037t, 2038

for ALL, 2017t

for bacterial meningitis, 1372–1373

for BPD, 2175

for PCOS, 1013

for PONV, 478t

for prostate cancer, 2094

for T-cell lymphomas, 2020t

Dexedrine (see Dextroamphetamine)

Dexlansoprazole, 483t, 1216t

PPI, 484, 485

Dexmedetomidine, 1213–1214

for pediatric intubation, 2200t

Dexmethylphenidate, for ADHD, 1867t

Dexrazoxane, 469t, 1980, 1981t, 1988–1989

Dextran component, 614

D

e

x

t

r

o

a

m

p

h

e

t

a

m

i

n

e

(

D

e

x

e

d

ri

n

e

)

,

4

6

8

t

,

1

7

7

8

D

e

x

t

r

o

m

e

t

h

o

rp

h

a

n

,

1

2

2

4

,

1

2

3

2

dis

s

o

c

ia

t

iv

e

drug

,

1

8

8

5

quinidin

e

c

o

mb

in

a

t

io

n

,

fo

r

a

g

it

a

t

e

d

b

e

h

a

v

io

r

s

,

2

2

4

3

D

e

x

t

r

o

rp

h

a

n

,

1

8

8

5

D

e

x

t

r

o

s

e

,

6

6

1

,

6

6

3

,

7

9

2

D

F

O

(

s

e

e

D

e

fe

r

o

x

a

m

i

n

e

(

D

F

O

)

)

D

H

A

(

s

e

e

D

i

c

o

s

o

h

e

x

a

n

o

i

c

a

c

i

d

(

D

H

A

)

)

D

H

A

P

,

fo

r

a

g

g

r

e

s

s

i

v

e

l

y

m

p

h

o

m

a

s

,

2

0

4

1

–

2

0

4

2

D

H

E

A

S

(

s

e

e

D

e

h

y

d

r

o

e

p

i

a

n

d

r

o

s

t

e

r

o

n

e

s

u

l

fa

t

e

(

D

H

E

A

S

)

)

D

H

T

(

s

e

e

D

i

h

y

d

r

o

t

e

s

t

o

s

t

e

r

o

n

e

(

D

H

T

)

)

D

i

az

e

p

a

m

,

5

6

5

,

9

8

8

,

1

1

8

6

t

,

1

7

3

7

t

,

1

7

4

2

,

1

7

4

6

,

2

1

3

1

t

fo

r

A

ka

th

is

ia

,

1

8

0

0

t

drug

int

e

r

a

c

t

io

n

w

ith

s

mo

kin

g

,

1

9

0

7

t

fe

b

r

ile

s

e

izur

e

s

a

n

d

,

1

2

9

5

P

C

P

-

in

du

c

e

d

s

e

izur

e

s

,

1

8

8

5

fo

r

p

e

dia

tr

ic

intub

a

t

io

n

,

2

1

9

9

t

in

S

E

,

1

2

9

9

fo

r

T

a

r

div

e

dy

s

kin

e

s

ia

,

1

8

0

1

D

i

b

e

n

z

o

x

az

e

p

i

n

e

,

1

7

8

9

t

D

i

b

e

n

z

o

yl

m

e

t

h

a

n

e

s

,

8

4

9

t

,

8

5

2

D

i

c

l

e

g

i

s

,

9

7

5

D

i

c

l

o

fe

n

a

c

,

5

5

,

8

7

0

t

,

8

7

1

,

8

8

7

,

8

8

8

t

,

1

1

8

7

t

D

i

c

l

o

fe

n

a

c

g

e

l

,

8

6

9

D

i

c

l

o

fe

n

a

c

p

a

t

c

h

,

8

6

9

D

i

c

l

o

fe

n

a

c

t

o

p

i

c

a

l

s

o

l

u

t

i

o

n

,

8

6

9

D

i

c

l

o

x

a

c

i

l

l

i

n

,

6

4

5

,

1

3

2

5

t

fo

r

s

kin

a

n

d

s

o

ft

t

is

s

u

e

in

fe

c

t

io

n

s

,

1

5

4

7

D

i

c

o

s

o

h

e

x

a

n

o

i

c

a

c

i

d

(

D

H

A

)

,

1

2

5

–

1

2

6

D

i

c

y

c

l

o

m

i

n

e

(

s

e

e

A

n

t

i

s

p

a

s

m

o

d

i

c

s

)

D

i

d

a

n

o

s

i

n

e

(

d

d

I

)

,

9

1

8

t

fo

r

H

I

V

,

1

5

7

8

t

fo

r

H

I

V

in

la

b

o

r

,

9

9

6

fo

r

H

I

V

-

r

e

la

t

e

d

a

n

e

mia

,

1

9

4

4

D

i

e

n

o

g

e

s

t

,

9

3

8

t

D

i

e

t

h

yl

c

a

rb

a

m

azi

n

e

,

fo

r

a

m

e

b

i

c

l

i

v

e

r

a

b

s

c

e

s

s

,

1

7

0

4

t

D

i

e

t

h

yl

p

r

o

p

i

o

n

,

7

6

2

D

i

e

t

h

yl

s

t

i

l

b

e

s

t

r

o

l

,

t

e

r

a

t

o

g

e

n

i

c

e

ffe

c

t

s

,

9

7

3

t

D

i

fi

c

i

d

(

s

e

e

F

i

d

a

x

o

m

i

c

i

n

)

D

i

fl

u

c

a

n

(

s

e

e

F

l

u

c

o

n

az

o

l

e

)

D

i

fl

u

n

i

s

a

l

,

8

7

0

t

D

i

g

i

t

a

l

i

s

(

D

i

g

o

x

i

n

)

,

1

2

8

,

2

1

4

,

4

8

4

,

6

6

5

,

9

1

4

t

,

2

1

3

1

t

fo

r

A

F

,

3

1

2

–

3

1

3

do

s

e

s

o

f,

2

9

1

p. 2

2

9

8

p. 2

2

9

9

drug

int

e

r

a

c

t

io

n

s

,

2

9

3

t

e

ffe

c

t

o

n

mo

r

t

a

lity

,

2

9

0–

2

9

1

e

ffic

a

c

y

o

f,

2

9

0

fo

r

H

F

,

2

6

8

,

2

7

1

a

n

d

hyp

e

r

ka

le

mia

,

5

8

5

fo

r

hyp

e

r

thyr

o

idis

m

,

1

0

5

7

monitoring parameters, 291

serum drug concentrations, 291

sex differences in response to, 291

toxicity, 292

withdrawal trials, 290

Digitalis glycosides, for HF, 290–293

Digoxin (see Digitalis)

Dihydroergotamine, 1239, 1240

Dihydropyridine calcium-channel blockers, for vascular dementia, 2242

Dihydrotestosterone (DHT), 826

Dilaudid (see Hydromorphone)

Diloxanide furoate, 1706

for amebicides, 1703t

Diltiazem, 120t, 128, 155–156, 214, 609, 1061, 2261t

for AF, 314

for HF, 275

for HFpEF, 271, 272

in patients with CKD, 617

for thyroid storm, 1067

Dimenhydrinate (Dramamine), 468t

for NVP, 975, 976t

Dimethyl fumarate, for MS, 1222, 1228

Dinoprostone cervical gel, 989–990

Dinoprostone slow-release insert (Cervidil), 989

Dinutuximab, 469t

Dioxybenzone, 849t, 852

Dipalmitoylphosphatidylcholine (DPPC), 2170

Dipentum (see Olsalazine)

Dipeptidyl peptidase-4 inhibitors (DPP-4)

adverse effects of, 1128

contraindications and precautions of, 1128

for diabetes, 2225

dosage and clinical use, 1128–1129

drug interactions, 1128

efficacy of, 1128

mechanism of action, 1127

pharmacokinetics of, 1127–1128

Diphenhydramine (Benadryl), 433t, 1776

for Akathisia, 1800t

for nocturnal leg cramps, 173

for NVP, 975, 976t

for Parkinsonism, 1799

for sleep, 1861

Diphenoxylate, 536

Diphenoxylate/atropine, 1449

Diphtheria, tetanus, and acellular pertussis (DTaP), 1355

vaccines, 1357

Dipyridamole, 1307t, 1314

Direct oral anticoagulants (DOACs), 178

advantages of, 187

dosing for AF and VTE, 179t

drug interactions with, 179t

for management of PE, 191

pharmacokinetic and pharmacodynamics properties of, 178t

for stroke prevention, 194

for VTE treatment, 194

Direct thrombin inhibitors

for heparin-induced thrombocytopenia, 178

injectable, 180t

Direct vasodilators, for hypertension, 140

Dirithromycin (Dynabac), 1325t

Diskus, for chronic asthma, 394, 396

Disopyramide

for HF, 275

for tachycardia, 1802

Disulfiram, alcohol withdrawal, 1897, 1898

Diuretics, 580

acetazolamide, 581

adverse effects of, 277–278

and azotemia, 277

and BNP, 278

combination therapy of, 279

for dysmenorrhea, 1015

for HF, 270

for hypertension, 140, 147–151

and hyperuricemia, 278

and hypokalemia, 150, 278

hypomagnesemia and, 151, 278

and hyponatremia, 151, 277–278, 581

loop, 580

and metabolic alkalosis/acidosis, 581

monitoring parameters with, 280t

for nephrotic edema, 574

osmotic, 581

for PMS, 1025

potassium-sparing, 580–581

thiazide, 580, 2261t

Divalproex, 1242, 1292, 1849t

Divigel (see Estradiol gel; Estradiol topical emulsion/gel/solution)

DLV (see Delavirdine (DLV))

DMARD, for RA, 891–899

DMPA (see Depot medroxyprogesterone acetate (DMPA))

DOACs (see Direct oral anticoagulants (DOACs))

Dobutamine, 212, 2207t, 2208

in cardiac failure, 363–364, 363t

for cardiogenic shock, 363–364

for HF, 271, 298

for septic shock, 371–372

for tachycardia, 365

Docetaxel, 469t, 475, 1978t, 1981t, 1983t, 1990

and hepatic dysfunction, 1996t

for NSCLC, 2062t, 2064t

peripheral nerve toxicity of, 1986

for prostate cancer, 2094

Docosanol cream (Abreva), 1650

Dofetilide

for AF, 316–317

for SuVT, 325

for tachycardia, 1802

for WPW, 320

Dolasetron (Anzemet), 472t

for PONV, 478t

Donepezil

for Alzheimer’s disease, 2238

for vascular dementia, 2242

Dopamine, 641, 689t, 1224, 2207t, 2208

for cardiac performance, 362–363, 363t

for cardiogenic shock, 362–363

GERD and, 503t

for HF, 271, 298

for hyperprolactinemia, 1802

for mild hypotension, 363–364

for NVP, 976t

for septic shock, 371–372

for Tardive dyskinesia, 1801

Dopamine agonists, 1252–1253, 1261–1262

adverse effects of, 1255–1256

dosage of, 1255

for Parkinson’s disease, 1253–1256

Doral (see Quazepam)

Doribax (see Doripenem)

Doripenem (Doribax), 1326t, 1371

for skin and soft tissue infections, 1550

Dornase alfa, 458–459

Dorzolamide (Trusopt), 1152

Doxazosin, 157t, 2256, 2261t

for BPH, 2256

in patients with CKD, 617

Doxepin (Silenor)

for depressive disorders, 1819t

for pruritus, 819

for treatment of insomnia, 1767t

Doxercalciferol, 622

Doxorubicin, 469t, 1977, 1978–1979t, 1978t, 1979, 1981t, 1983t, 1987–1988, 2003, 2005, 2040t, 2042

for ALL, 2017t

for breast cancer, 2052, 2053

and cardiomyopathy, 1987–1988

cardiotoxicity of, 2007

gonadal toxicity of, 1998

for HL, 2041

for osteosarcoma, 2008

for rhabdomyosarcoma, 2010, 2011

for T-cell lymphomas, 2020t

Doxycycline, 927, 942t, 1325t, 1698t, 1720, 1723

for cellulitis, 645

for acne, 828, 829

for COPD, 418

dosing of, 1337t

for lymphogranuloma venereum, 1515

for malaria prophylaxis, 49

for PID, 1512–1513t

for skin and soft tissue infections, 1547, 1552

in UTI, 1501

for HGA, 1726

for HME, 1726

fo

r

L

yme

dis

e

a

s

e

,

1

7

2

0

fo

r

R

M

S

F

,

1

7

2

5

fo

r

T

B

R

F

,

1

7

2

3

fo

r

tula

r

e

mia

,

1

7

2

4

D

o

x

yl

a

m

i

n

e

,

1

7

7

6

fo

r

N

V

P

,

9

7

5

,

9

7

6

t

p. 2

2

9

9

p. 2

3

0

0

D

P

P

-

4

(

s

e

e

D

i

p

e

p

t

i

d

yl

p

e

p

t

i

d

a

s

e

-

4

i

n

h

i

b

i

t

o

r

s

(

D

P

P

-

4

)

)

D

P

P

C

(

s

e

e

D

i

p

a

l

m

i

t

o

yl

p

h

o

s

p

h

a

t

i

d

yl

c

h

o

l

i

n

e

(

D

P

P

C

)

)

D

r

a

m

a

m

i

n

e

(

s

e

e

D

i

m

e

n

h

y

d

ri

n

a

t

e

)

D

r

o

n

a

b

i

n

o

l

(

M

a

ri

n

o

l

)

,

4

7

2

t

,

1

2

0

4

D

r

o

n

e

d

a

r

o

n

e

,

1

2

0

t

fo

r

A

F

,

3

1

6–

3

1

7

fo

r

H

F

,

2

7

5

D

r

o

p

e

ri

d

o

l

(

I

n

a

p

s

i

n

e

)

,

4

7

2

t

fo

r

N

V

P

,

9

7